Cholesterol 1,2,3 skin test
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer & Specialty Pharmaceuticals is on short list of potential U.S. marketing partners for International Medical Innovations' Cholesterol 1,2,3 test. McNeil will market the three-minute, non-invasive cholesterol skin test in Canada; however, Toronto-based IMI says it is considering U.S. distribution deals with several other firms. Cholesterol 1,2,3 received FDA 510(k) clearance on June 24; it is indicated for use with standard blood testing for patients suspected of having severe coronary artery disease. Home version of the test is under development, IMI says...
You may also be interested in...
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.